Research Analysts Offer Predictions for TNGX Q2 Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Analysts at HC Wainwright upped their Q2 2025 EPS estimates for Tango Therapeutics in a research report issued to clients and investors on Monday, June 30th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.35) for the quarter, up from their prior forecast of ($0.37). HC Wainwright has a "Buy" rating and a $13.00 price objective on the stock. The consensus estimate for Tango Therapeutics' current full-year earnings is ($1.19) per share. HC Wainwright also issued estimates for Tango Therapeutics' Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.45) EPS, Q2 2026 earnings at ($0.40) EPS and Q4 2026 earnings at ($0.37) EPS.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.02). Tango Therapeutics had a negative return on equity of 62.75% and a negative net margin of 322.67%. The business had revenue of $5.39 million during the quarter, compared to analysts' expectations of $6.73 million.

Tango Therapeutics Stock Performance

TNGX stock traded up $0.04 on Wednesday, reaching $5.69. The company's stock had a trading volume of 620,177 shares, compared to its average volume of 1,580,456. The business has a fifty day simple moving average of $2.99 and a two-hundred day simple moving average of $2.55. Tango Therapeutics has a 12-month low of $1.03 and a 12-month high of $12.02. The firm has a market cap of $616.74 million, a PE ratio of -4.66 and a beta of 1.63.

Hedge Funds Weigh In On Tango Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Teacher Retirement System of Texas lifted its position in Tango Therapeutics by 35.8% during the fourth quarter. Teacher Retirement System of Texas now owns 14,544 shares of the company's stock valued at $45,000 after buying an additional 3,831 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Tango Therapeutics by 29.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 20,998 shares of the company's stock valued at $65,000 after buying an additional 4,813 shares during the period. Deutsche Bank AG lifted its position in Tango Therapeutics by 24.1% during the fourth quarter. Deutsche Bank AG now owns 36,653 shares of the company's stock valued at $113,000 after buying an additional 7,128 shares during the period. Wells Fargo & Company MN lifted its position in Tango Therapeutics by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 22,292 shares of the company's stock valued at $69,000 after buying an additional 7,599 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in Tango Therapeutics by 9.9% during the first quarter. Bank of New York Mellon Corp now owns 113,233 shares of the company's stock valued at $155,000 after buying an additional 10,213 shares during the period. Hedge funds and other institutional investors own 78.99% of the company's stock.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.